Remibrutinib significantly reduces itch and hives in patients with chronic spontaneous urticaria in two identical randomized ...

In this randomized controlled trial, among patients with chronic spontaneous urticaria who continue to have symptoms while on ...

For patients with symptomatic chronic spontaneous urticaria after treatment with second-generation H1-antihistamines, ...

A new groundbreaking study revealed that Remibrutinib showed promising results in treating chronic spontaneous urticaria.A recent study published in the New England Journal of Medicine outlined the ...

Novartis (NOVN: VX) has reported new data showing that its investigational BTK inhibitor, remibrutinib, significantly ...

The advent of remibrtuinib, a Bruton's tyrosine kinase inhibitor, may encourage dermatologists to take care of chronic spontaenous urticaria patients, says a presenter at the 2025 meeting of the ...

Dr Adam Friedman recounts how AAD 2025 highlighted advancements in chronic spontaneous urticaria management, with discussion on new therapies and the role of diet.

Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long ...

Cases of liver toxicity in trials have, however, pegged back expectations for tolebrutinib and other drugs in the oral BTK class in late-stage testing for MS, which include remibrutinib ...

Martin Metz, M.D., from Charité–Universitätsmedizin Berlin, and colleagues examined the efficacy and safety of remibrutinib in patients with symptomatic chronic spontaneous urticaria after treatment ...